Ryvu Therapeutics, a clinical-stage drug discovery company based in Kraków, Poland, has announced a strategic partnership with BioNTech to accelerate access to investigational cancer immunotherapies for Polish patients. The agreement positions Ryvu to support trial site activation and patient recruitment for multiple BioNTech oncology programs across Poland.
Strategic Partnership Framework
Under the agreement, Ryvu will leverage its operational excellence, expertise in oncology clinical operations, and existing trial site network to streamline Polish patient access to BioNTech's investigational immunotherapies. BioNTech intends to design and roll out clinical trials for some of the company's priority programs in Poland while funding Ryvu's services under the partnership.
The clinical programs planned for inclusion span multiple solid tumor types, including lung, breast, and colorectal cancers. This broad scope reflects both companies' commitment to addressing diverse oncological needs within the Polish patient population.
Leveraging Clinical Infrastructure
Kamil Sitarz, Chief Operating Officer and Management Board Member of Ryvu Therapeutics, emphasized the partnership's foundation on existing collaboration. "We are thrilled to build on our strong research relationship with BioNTech by entering a strategic agreement that leverages Ryvu's operational excellence and expertise in oncology clinical operations to bring more BioNTech clinical programs to Poland," Sitarz stated.
He highlighted the synergistic potential of the partnership, noting that "BioNTech's science and innovation, combined with our shared ambition to bring innovative treatments to patients quickly, create a powerful momentum. We look forward to working together to streamline clinical trial activation and patient recruitment for BioNTech's cancer immunotherapy clinical trials in Poland."
Company Background and Capabilities
Ryvu Therapeutics operates as a clinical-stage drug discovery and development company focused on novel oncology therapies targeting emerging cancer biology mechanisms. The company's internal pipeline includes small molecules and antibody-drug conjugates directed at kinases, synthetic lethality, and immuno-oncology targets.
The company's most advanced program, RVU120, is a selective CDK8/CDK19 kinase inhibitor currently in Phase II development across multiple hematological malignancies. Additional programs include dapolsertib (MEN1703, SEL24), a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, and RVU305, a brain-permeable PRMT5 inhibitor in IND/CTA-enabling studies.
Founded in 2007 and headquartered in Kraków, Ryvu is listed on the Warsaw Stock Exchange as a component of the sWIG80 index. The company maintains existing oncology collaborations with both BioNTech and Exelixis, positioning it as an experienced partner in international clinical development initiatives.
